Market Overview:
The global human microbiome therapeutic drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of lifestyle diseases, rising awareness about the benefits of probiotics and prebiotics, and growing demand for personalized medicines. The global human microbiome therapeutic drugs market can be segmented on the basis of type into FMT (fecal microbiota transplantation), microbiome drugs, and others. On the basis of application, this market can be segmented into stomach, oral cavity, respiratory tract, and others. Geographically, this market can be segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . Some key players operating in this global human microbiome therapeutic drugs market are AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc,, Ferring Pharmaceuticals AG,, Enterome Bioscience SAS,, Seres Therapeutics,.
Product Definition:
A human microbiome therapeutic drug is a medication that is designed to treat disorders or conditions that are associated with the human microbiome. The human microbiome refers to the collection of microorganisms that live on and in the body. These microorganisms play a role in many aspects of health and disease, including digestion, metabolism, and immune function. There are many potential disorders or conditions that may be treated with drugs designed to target the human microbiome, including obesity, diabetes, irritable bowel syndrome (IBS), and autoimmune diseases.
FMT:
The global fecal microbiota transplant (FMT) market size was valued at USD 3.6 million in 2015 and is expected to grow at a CAGR of XX% over the forecast period. FMT is a procedure wherein healthy stool or colonic bacteria are transplanted into the patient's body, usually for treating Clostridium difficile (C difficile) infections which are associated with severe diarrhea.
Microbiome Drugs:
Microbiome Therapeutic Drugs Market Size, Share & Trends Analysis Report By Type (Fungal, Bacterial), By Application (Cancer Treatment, Autoimmune Disease Treatment), And Segment Forecasts, 2018 - 2025 -> The global microbiome therapeutics drugs and it's usage in human microbiome therapeutic drugs market size was valued at USD 7.96 billion in 2017 and is expected to register a CAGR of XX% during the forecast period.
Application Insights:
The others segment held the largest share of over 50.0% in 2017. The other applications include brain, lung, breast and gut microbiome therapeutic drugs. Breast milk is a natural source of many useful proteins that can be used as therapeutics for various diseases such as infant diarrhea and allergies due to its immunomodulatory properties. However, there are no approved products for use in this population thus making it difficult for healthcare providers to implement these therapies despite their benefits compared to standard care alone.
Stomach was the second-largest application segment with a revenue share of over 19% in 2017 owing to high product demand from Europe and North America regions where H pylori infection is common due to lack of effective treatment options against this bacterial infection which causes about 20 million infections per year globally according to UHNWI Global Health Intelligence Center (UHGHC).
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to extensive research and development undertaken by key companies, such as Alvine Pharmaceuticals, Inc.; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; and OpenBiome Therapeutics, Inc., for commercialization of products targeting the human microbiome in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing R&D investments by pharmaceutical companies for development of novel therapies based on micro-organisms or their products derived from these microbes (termed as biologics). For instance, Novozymes A/S has developed a new type of probiotic called Synulox that contains live bacteria strains useful against diarrhea caused due to rotavirus infection which are currently used in prophylaxis only after disease occurrence [1].
Growth Factors:
- Increasing incidence of chronic diseases such as obesity, diabetes, and cancer is expected to drive the demand for human microbiome therapeutic drugs over the forecast period.
- Growing awareness about the benefits of human microbiome therapy is anticipated to boost market growth.
- Rising number of research and development activities for novel human microbiome therapeutics is projected to propel market expansion during the forecast period.
- Technological advancements in drug delivery systems are likely to create new opportunities for market growth over the next few years. 5) The increasing use of probiotics as a dietary supplement is also expected to fuel demand for human microbiome therapeutic drugs in the near future
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Microbiome Therapeutic Drugs Market Research Report
By Type
FMT, Microbiome Drugs, Others
By Application
Stomach, Oral, Respiratory Tract, Others
By Companies
Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb, Johnson and Johnson, Takeda, ENTEROME Bioscience
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Human Microbiome Therapeutic Drugs Market Report Segments:
The global Human Microbiome Therapeutic Drugs market is segmented on the basis of:
Types
FMT, Microbiome Drugs, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Stomach, Oral, Respiratory Tract, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Rebiotix
- Seres Therapeutics
- Vedanta Biosciences
- Bristol-Myers Squibb
- Johnson and Johnson
- Takeda
- ENTEROME Bioscience
Highlights of The Human Microbiome Therapeutic Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- FMT
- Microbiome Drugs
- Others
- By Application:
- Stomach
- Oral
- Respiratory Tract
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Microbiome Therapeutic Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human microbiome therapeutic drugs are medications that are designed to treat or prevent diseases by affecting the human microbiome.
Some of the major players in the human microbiome therapeutic drugs market are Rebiotix, Seres Therapeutics, Vedanta Biosciences, Bristol-Myers Squibb, Johnson and Johnson, Takeda, ENTEROME Bioscience.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Microbiome Therapeutic Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Microbiome Therapeutic Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Microbiome Therapeutic Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Microbiome Therapeutic Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Microbiome Therapeutic Drugs Market Size & Forecast, 2018-2028
4.5.1 Human Microbiome Therapeutic Drugs Market Size and Y-o-Y Growth
4.5.2 Human Microbiome Therapeutic Drugs Market Absolute $ Opportunity
Chapter 5 Global Human Microbiome Therapeutic Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Human Microbiome Therapeutic Drugs Market Size Forecast by Type
5.2.1 FMT
5.2.2 Microbiome Drugs
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Human Microbiome Therapeutic Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Human Microbiome Therapeutic Drugs Market Size Forecast by Applications
6.2.1 Stomach
6.2.2 Oral
6.2.3 Respiratory Tract
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Microbiome Therapeutic Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Microbiome Therapeutic Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Human Microbiome Therapeutic Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Human Microbiome Therapeutic Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Human Microbiome Therapeutic Drugs Market Size Forecast by Type
9.6.1 FMT
9.6.2 Microbiome Drugs
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Human Microbiome Therapeutic Drugs Market Size Forecast by Applications
9.10.1 Stomach
9.10.2 Oral
9.10.3 Respiratory Tract
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Human Microbiome Therapeutic Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Human Microbiome Therapeutic Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Human Microbiome Therapeutic Drugs Market Size Forecast by Type
10.6.1 FMT
10.6.2 Microbiome Drugs
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Human Microbiome Therapeutic Drugs Market Size Forecast by Applications
10.10.1 Stomach
10.10.2 Oral
10.10.3 Respiratory Tract
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Human Microbiome Therapeutic Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Human Microbiome Therapeutic Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Human Microbiome Therapeutic Drugs Market Size Forecast by Type
11.6.1 FMT
11.6.2 Microbiome Drugs
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Human Microbiome Therapeutic Drugs Market Size Forecast by Applications
11.10.1 Stomach
11.10.2 Oral
11.10.3 Respiratory Tract
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Human Microbiome Therapeutic Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Human Microbiome Therapeutic Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Human Microbiome Therapeutic Drugs Market Size Forecast by Type
12.6.1 FMT
12.6.2 Microbiome Drugs
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Human Microbiome Therapeutic Drugs Market Size Forecast by Applications
12.10.1 Stomach
12.10.2 Oral
12.10.3 Respiratory Tract
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Human Microbiome Therapeutic Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Human Microbiome Therapeutic Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Human Microbiome Therapeutic Drugs Market Size Forecast by Type
13.6.1 FMT
13.6.2 Microbiome Drugs
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Human Microbiome Therapeutic Drugs Market Size Forecast by Applications
13.10.1 Stomach
13.10.2 Oral
13.10.3 Respiratory Tract
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Microbiome Therapeutic Drugs Market: Competitive Dashboard
14.2 Global Human Microbiome Therapeutic Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Rebiotix
14.3.2 Seres Therapeutics
14.3.3 Vedanta Biosciences
14.3.4 Bristol-Myers Squibb
14.3.5 Johnson and Johnson
14.3.6 Takeda
14.3.7 ENTEROME Bioscience
